Collegium's $155M Pain Engine Is Funding a Bigger ADHD Multiple

JORNAY PM is becoming the valuation story while pain still funds it

The market is still judging Collegium mostly as a pain company. The more interesting setup is a portfolio re-rating: ADHD grows into the main growth narrative while the pain business remains the cash engine that supports the transition.

The mix explains why. In the first quarter, the pain portfolio still produced $154.6 million of net revenue, but JORNAY PM already contributed $38.9 million. That combination matters more than the headline growth rate. A business generating that level of pain revenue can keep investing in ADHD while investors decide whether the company deserves a higher multiple on a faster-growing franchise.

That is why the next report matters. Collegium reports again on August 6, 2026. The core question is whether JORNAY PM can keep building momentum and improving mix enough to shift the narrative. If ADHD continues to progress and execution stays clean, investors may start valuing Collegium less like a legacy pain company and more like an ADHD-focused growth story.

Why the pain franchise still matters even if investors discount it

The key question is not just what multiple the pain business deserves. It is what the pain business is still doing for Collegium. At this stage, pain is not the future headline growth engine; it is the annuity that keeps the ADHD expansion credible.

Stable pain cash flow gives ADHD time

Management described modest pressure in the pain portfolio, not a break in demand. That distinction matters. The upside case does not require pain to re-rate. It requires pain to stay relatively stable while ADHD scales.

That stability matters because JORNAY PM is already expected to generate $190M–$200M (~31% YoY at midpoint). If the pain portfolio softens only modestly, investors can keep financing that growth and still give ADHD more credit. If pain weakens too sharply, though, the market is likely to treat ADHD expectations less generously.

The internal mix still looks controlled

The quarter did not show a franchise losing credibility. From the earnings transcript, Nucynta franchise net revenue...flat, while Belbuca net revenue showed a 2% year-over-year increase. That points to a business normalizing rather than breaking.

The near-term setup, then, is fairly clear: the opportunity is not finding a higher multiple for pain. It is recognizing that pain is funding a potentially higher multiple for ADHD. The main watchpoint is whether that cushion holds.